Human IL-6 ELISA Assay Kit

Detectable values in serum and plasma samples

We´re thrilled to offer our customers a SIGNIFICANT PRICE DROP of minus 15% !!!

on our human Interleukin-6 ELISA assay kit.

Quality, fully validated kit, ready to use reagents for affordable and efficient research!

Biomedica´s human Interleukin-6 (IL-6) ELISA is highly sensitive with measurable values in serum and in plasma samples.

Features include:

• Standardized– use of WHO intern. standards for kit calibration & harmonization 
• High Specificity – using characterized epitope-mapped antibodies
• User-Friendly – ready to use color coded, prediluted standards & controls

 

Human IL-6 ELISA Assay Kit (cat. no. BI-IL6)

Contact us or your local representative click here

Just use Promotion Code: BCIL62024 on your order.

Human IL-6 ELISA Assay Kit (cat. no. BI-IL6)

• Format: 12×8 wells
• Detection limit/Sensitivity: 0.28 pg/ml
• Assay – Dynamic Range: 0 – 200 pg/ml
• Incubation Time: 4 hours 30 minutes
• Sample Type: Serum, Plasma, Cell Culture Supernatants, Urine
• Sample Volume: 100 µl
• Alternative Name: Interleukin 6

 

Links to IL-6 ELISA : Protocol Booklet,  Validation Data File, Material Safety Data Sheet MSDS

The Human IL-6 High Sensitivity ELISA Assay is Developed and Manufactured in Austria by Biomedica

 Assay Principle

The Human IL-6 High Sensitivity ELISA Assay Kit is a sandwich enzyme immunoassay that has been optimized and fully validated for the quantitative determination of human IL-6 in serum, EDTA-plasma, citrate plasma, and heparin plasma. Validation experiments have been performed according to international quality guidelines (ICH/ FDA/ EMEA). Cell culture supernatant and urine samples are compatible with this ELISA. The IL-6 ELISA assay recognizes both natural and recombinant human IL-6. The assay employs highly purified epitope mapped antibodies as well as human serum-based standards and controls. The figure below explains the principle of the human IL-6 sandwich ELISA:

First, STD/sample/CTRL are pipetted into wells. The wells are precoated with a recombinant anti-human IL-6 antibody. The soluble IL-6 that is present in the sample binds to the pre-coated anti-IL-6 antibody in the well. After an incubation step, the microtiter plate is washed where all non-specific unbound material is removed. In the next step, the biotinylated anti-IL-6 antibody is pipetted into the wells. This antibody reacts with the IL-6 present in the sample and forms a so-called sandwich. During the next washing step all unbound antibody is removed. After washing, the conjugate (streptavidin-HRPO) is added to the wells that reacts with the biotinylated anti-IL-6 antibody. After a further washing step, the substrate (tetramethylbenzidine; TMB) is pipetted into the wells. The enzyme catalyzed color change of the substrate is directly proportional to the amount of IL-6 present in the sample which is detectable with a standard microtiter plate ELISA reader. Thereafter, a dose response curve of the absorbance (optical density, OD at 450 nm) versus standard concentration is generated, using the values obtained from the standards. The concentration of soluble IL-6 in the sample is determined directly from the dose response curve.

Learn more about our validation process and our quality guidelines

Related ELISA kits

Human VEGF, human Angiopoietin-2, mouse/rat Angiopoietin-2

 

About Interleukin-6 (IL- 6)

Il-6 is a cytokine which acts as a type of signaling molecule that plays a critical role in the immune response, inflammation, and metabolism. It is produced by various types of cells, including macrophages, T cells, and fibroblasts, and acts on multiple cell types to modulate immune functions and systemic responses.

Key Functions of IL-6

1. Role in Inflammation: IL-6 is involved in the acute phase response to inflammation and infection. It stimulates the production of acute-phase proteins by the liver, such as C-reactive protein (CRP).
2. Immune Regulation: This cytokine influences the differentiation of T cells and B cells, enhancing the body’s ability to respond to pathogens. It also promotes the growth and differentiation of specific immune cells.
3. Metabolism: IL-6 plays a role in metabolic processes, including glucose metabolism and lipid metabolism. Dysregulation of IL-6 signaling is linked to metabolic disorders such as obesity and type 2 diabetes.
4. Bone Metabolism: IL-6 is involved in bone remodeling. It can stimulate the formation of osteoclasts, the cells responsible for bone resorption, potentially contributing to conditions such as osteoporosis.
5. Chronic Conditions: Elevated levels of IL-6 are associated with chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and certain malignancies. It is also implicated in the cytokine storm seen in severe cases of COVID-19.

 

Clinical Relevance

Due to its central role in inflammation and immune response, IL-6 has become a target for therapeutic interventions in various conditions. Several IL-6 inhibitors, such as tocilizumab, are used in the treatment of autoimmune diseases and other inflammatory conditions. Monitoring IL-6 levels can also provide insights into disease progression and response to treatment in conditions characterized by inflammation.

Conclusion:

IL-6 is a multifaceted cytokine with critical roles in immune responses, inflammation, and metabolism. Its dysregulation can contribute to various diseases, making it an important focus in both research and clinical settings. Understanding its mechanisms and effects can help in developing targeted therapies for inflammatory and metabolic disorders.

Literature

• Interleukin 6: at the interface of human health and disease. Grebenciucova E, VanHaerents S. Front Immunol. 2023 Sep 28;14:1255533. doi: 10.3389/fimmu.2023.1255533. PMID: 37841263; PMCID: PMC10569068.
• Interleukin-6 signalling in health and disease. Rose-John S. F1000Res. 2020 Aug 20;9:F1000 Faculty Rev-1013. doi: 10.12688/f1000research.26058.1. PMID: 32864098; PMCID: PMC7443778.
• Recent advances in the role of interleukin-6 in health and disease. Peppler WT, Townsend LK, Wright DC. Curr Opin Pharmacol. 2020 Jun;52:47-51. doi: 10.1016/j.coph.2020.04.010. Epub 2020 Jun 18. PMID: 32563931.